MAPS Psychedelic Research Presentation at 2011 Women's Visionary Congress

The Multidisciplinary Association for Psychedelic Studies (MAPS) is presented by two staff members as a non-profit pharmaceutical approach to developing MDMA and other psychedelics into prescription medicines for conditions like PTSD. The presentation outlines their unique clinical trial model, which integrates drug-based sessions with non-drug therapeutic support. They emphasize the importance of a nurturing environment, a male/female co-therapist team, and the inclusion of diverse participant populations to ensure comprehensive and representative findings. Furthermore, the speakers delve into the specific details of their MDMA-assisted psychotherapy for PTSD, highlighting the therapeutic potential reflected in patient outcomes, which include reduced symptom severity and overall well-being. They contrast this with traditional pharmacological research, stressing that MAPS operates with a focus on holistic healing, safety, and scientific validity. The talk concludes with an update on their ongoing studies, indicating progress in trials for various conditions and highlighting their ongoing community outreach efforts.